阿尔茨海默病:病理生物学和治疗策略的最新情况
Justin M Long1, David M Holtzman1
1Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cell
|October 1, 2019
概括
阿尔茨海默氏病 (AD) 涉及的不仅仅是粉样斑块和团. 研究突出了新的细胞过程, 但仍然需要有效的疾病修饰治疗.
科学领域:
- 神经学
- 神经科学
- 病理生物学
背景情况:
- 阿尔茨海默病 (AD) 的特征是粉样斑块和神经纤维结.
- 最近的发现揭示了AD病理生物学中的其他关键细胞和分子过程.
- 目前阿尔茨海默病的治疗方法没有改变疾病, 临床试验也取得了有限的成功.
研究的目的:
- 了解阿尔茨海默病病理生物学方面的最新进展.
- 讨论目前的阿尔茨海默病治疗策略和临床试验.
- 找出开发阿尔茨海默氏症疾病修饰疗法的机会.
主要方法:
- 对阿尔茨海默症病理学近期基本发现的文献综述.
- 分析目前的治疗策略和第三阶段临床试验结果.
- 探索新兴治疗点的研究.
主要成果:
- 阿尔茨海默病的病理生物学比以前更复杂,涉及多种细胞和分子途径.
- 尽管进行了广泛的研究,但目前还没有确切的疾病修饰治疗方法.
- 许多临床试验未能证明有显著的益处,强调需要新的方法.
结论:
- 对阿尔茨海默病的复杂病理生物学有全面的了解,对于开发有效的治疗方法至关重要.
- 未来阿尔茨海默病的治疗策略必须考虑更广泛的病理机制.
- 继续研究新的目标和方法对于促进阿尔茨海默病治疗至关重要.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.7K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.7K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526
Amyloid Fibrils
11.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.7K
